Related Experiment Videos
Temozolomide: realizing the promise and potential.
R Nagasubramanian1, M Eileen Dolan
1Department of Pediatrics, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Illinois 60637, USA.
Current Opinion in Oncology
|November 19, 2003
Summary
Temozolomide shows promise for brain tumors but has limited efficacy in current use. Combining it with resistance modifiers may improve outcomes, but larger trials are needed.
Area of Science:
- Neuro-oncology
- Pharmacology
- Clinical Trials
Background:
- Temozolomide (TMZ) discovery aimed to improve survival in malignant brain tumors.
- TMZ demonstrated activity against refractory gliomas and other malignancies.
- Recent research explores optimizing TMZ efficacy through dosing and combination therapies.
Purpose of the Study:
- To review recent studies on temozolomide efficacy and optimization strategies.
- To evaluate the current role of temozolomide in treating malignant brain tumors.
- To identify future directions for temozolomide-based therapies.
Main Methods:
- Critical review of clinical studies on temozolomide.
- Analysis of temozolomide efficacy in various tumor types and treatment settings.
- Evaluation of safety profiles and dosing schedules.
Main Results:
- Temozolomide shows limited efficacy in refractory malignant brain tumors, with marginal survival benefit over procarbazine.
- Positive activity noted in recurrent low-grade gliomas and advanced melanomas.
- All tested dosing schedules show favorable safety, but many trials lack controls and adequate follow-up.
Conclusions:
- Temozolomide's full potential remains unrealized despite its safety and oral administration.
- Combination with drug resistance modifiers may enhance disease control and survival.
- Larger, randomized trials are essential to confirm temozolomide's benefit in malignant brain tumors.